中國醫藥(600056.SH):重要參股公司籌劃變更實際控制人事項
格隆匯2月5日丨中國醫藥(600056.SH)公佈,收到控股股東中國通用技術(集團)控股有限責任公司的吿知函,通用技術集團正在與重慶化醫控股(集團)公司(簡稱“重慶化醫”)開展重慶醫藥健康產業有限公司(簡稱“重慶醫藥”)戰略整合事宜,本次整合或將導致重慶醫藥的控股股東和實際控制人變更為通用技術集團。
通用技術集團持有重慶醫藥22%股權,公司持有重慶醫藥27%股權,作為公司重要參股公司,如通用技術集團取得對重慶醫藥的控制權,由此可能會帶來與公司的同業競爭,通用技術集團將嚴格按照相關法律、法規的規定履行各項承諾並及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.